Core Viewpoint - The company, Bory Pharmaceutical (Suzhou) Co., Ltd., has announced that its subsidiary, Bory Pharmaceutical, is expected to be selected for the national drug procurement program, which could significantly impact its sales and market presence [1][2]. Group 1: Product Selection Details - The company participated in the national drug procurement program for products whose agreements have expired, with the selection results published on February 10, 2026 [1]. - Four products from the company are expected to be selected, which accounted for a total sales revenue of 88.8475 million yuan in the first three quarters of 2025, representing 10.16% of the company's total revenue during that period [2]. Group 2: Impact of Selection - The procurement cycle for the selected products will last until December 31, 2028, with medical institutions prioritizing the use of these selected drugs, which is expected to enhance sales volume and market share [2]. - If contracts are signed and implemented, it will further boost the company's brand image and sales performance [2].

格隆汇2月11日丨博瑞医药（维权）(688166.SH)公布，公司全资子公司博瑞制药（苏州）有限公司 （称"博瑞制药"）参加了国家组织集采药品协议期满品种接续采购办公室(称"接续采购办公室")组织的 集采药品协议期满品种接续采购(称"本次接续采购")。根据接续采购办公室于2026年2月10日发布的 《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公司部分药品拟中选本次接续采购。 本次接续采购品种为第1-8批国家组织集采协议期满的品种，约定采购量以医药机构填报各企业采购品 种需求量为基数，按照中选价格梯度确定带量比例。采购周期自中选结果实际执行日起至2028年12月31 日。 公司上述拟中选的4个产品2025年前三季度合计销售额为8,884.75万元，占公司2025年前三季度营业收入 比例为10.16%。在采购周期内，医疗机构将优先使用本次药品接续采购中选药品，并确保完成约定采 购量。若后续签订采购合同并实施，将进一步扩大产品的销量，提高市场占有率，提升公司品牌形象。 ...